Log In
Print
BCIQ
Print
Print this Print this
 

MVA-MUC1-IL2 (TG4010)

  Manage Alerts
Collapse Summary General Information
Company Transgene S.A.
DescriptionRecombinant Modified Vaccinia Ankara (MVA) virus vector encoding the mucin 1 (MUC1; CD227) tumor-associated antigen and IL-2
Molecular Target Mucin 1 (MUC1) (CD227) ; Interleukin-2 (IL-2)
Mechanism of ActionVaccine
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPhase II/III
Standard IndicationNon-small cell lung cancer (NSCLC)
Indication DetailsTreat advanced or metastatic MUC1-positive non-small cell lung cancer (NSCLC) stage IIIB or IV; Treat non-small cell lung cancer (NSCLC)
Regulatory Designation

U.S. - Fast Track (Treat non-small cell lung cancer (NSCLC))

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today